lol, depends how you define undervalued. IMO the elements are not there unless you determine that either the SP or the business model are going to kick on, because at this stage there is no return on investment, so it is only speculative. You would have to demonstrate conclusively where the investment return is to be able to call it undervalued.
However........................some people like to use AI as an information source and our mutual friend TheAnalyst007s
Post #: 75183504 seems to have achieved some sort of notoriety for him as a market analyst, lined up alongside Simply Wall Street as an authoritative source of information......
This is too funny to get hung up about, but all I can say is norty norty 007, your post is full of ahem..............inaccuracies lol
Based on the search results, there are indications that Nova Eye Medical Limited (ASX:EYE) may be undervalued: According to a Simply Wall St analysis, Nova Eye Medical's fair value estimate is AU$0.40, which suggests the stock could be 43% undervalued compared to its current share price of AU$0.23 A HotCopper forum post from August 2024 argues that Nova Eye Medical is "incredibly undervalued" with a valuation estimate of $1 per share based on peer analysis and reported revenue run rate Key points include: Market cap of $50 million Revenue of $23 million in FY24, with a run rate of $28 million Cash position of about $10 million and no debt 80% revenue growth reported in the last half Launch of a new device in the growing Minimally Invasive Glaucoma Surgery market The company has two main business segments - glaucoma treatments and retinal treatments (2RT), with the iTrack Advance device for glaucoma described as potentially becoming a "gold standard" treatment As of September 2024, Nova Eye Medical had a market cap of $48.10 million and a share price of 21.0 cents Some analysts believe the broader healthcare sector is undervalued going into 2024, which could potentially apply to Nova Eye Medical as well However, it's important to note that valuation is complex and subjective. While these sources suggest Nova Eye Medical may be undervalued, investors should conduct their own research and consider multiple factors before making investment decisions. The company's future performance will depend on factors like market adoption of its products, competitive landscape, and overall financial execution. 
(20min delay)